Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €4.84 EUR
Change Today +0.04 / 0.83%
Volume 66.9K
As of 3:35 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Thomas Taapken Ph.D.

Chief Executive Officer, Chief Financial Officer and Member of Executive Board,Epigenomics AG
AgeTotal Calculated CompensationThis person is connected to 21 board members in 2 different organizations across 5 different industries.

See Board Relationships
As of Fiscal Year 2014


Dr. Thomas Taapken, Ph.D. has been the Chief Executive Officer of Epigenomics AG since April 1, 2013 and its Chief Financial Officer since April 1, 2011 and also serves as its Member of Management Board. Dr. Taapken served as the Chief Financial Officer at Elbion AG (alternate name elbion GmbH). He served as Chief Financial Officer of elbion NV since September 2005. He served as Chief Financial Officer at Biotie Therapies Corp. from September 2005 to March 31, 2011 and ...

Read Full Background

Corporate Headquarters*

Geneststrasse 5
Berlin, -- 10829


Phone: 49 30 243 450
Fax: 49 30 2434 5555

Board Members Memberships*

There is no Board Members Memberships data available.


Technische Universität Berlin

Other Affiliations*

Annual Compensation*

Total Annual Compensation€377,260

Stock Options*

Long Term Incentive Plan€101,068

Total Compensation*

Total Annual Cash Compensation€377,260
Total Short Term Compensation€377,260
Total Calculated Compensation€478,328
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ECX:GR €4.84 EUR +0.04


There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EPIGENOMICS AG, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at